Cobra Biologics acquires Unitech Pharma
Under the terms of the agreement, Cobra Biologics will acquire 100% of the shareholding in Unitech Pharma Group, which provides a 600L clinical and commercial microbial GMP production capacity, commercial aseptic fill/finish and lyophilisation capability.
Peter Coleman, CEO of Cobra commented: “I am delighted to announce this acquisition as it significantly enhances Cobra’s service offering to our customers. The facility in Matfors will bring over 20 years of bio-production experience to Cobra, with their offering perfectly complimenting Cobra’s existing expertise and capacity. This is the first step as a newly independent business in our intention to expand and grow our business, to provide the best possible service for our customers.”
Cobra’s comprehensive service offering now includes cell line development, analytical and process development, GMP production, fill/finish, product release for phase I, II, III clinical trials and in-market supply.